A brief introduction to Cantargia

To the interview

CANFOUR clinical results, interview

To the interview (in Swedish)

Cantargia listed on Nasdaq Stockholm (Small Cap)

Read more

Two Nobel Prizes with utmost significance for Cantargia’s research

Read more

Latest press releases

(R) Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

(R) Cantargia announces new pre-clinical results showing consistent positive effects of the antibody CAN04 when combined with platinum-based chemotherapies

(R) Cantargia signs agreement with Patheon Biologics B.V. for production of antibody CAN04

* (R) = Regulatory press releases

In 2018 we completed the first very important steps in the clinical development of CAN04 and presented patient data that boosted our hopes that CAN04 could form an important part of the future of cancer treatment.” – Göran Forsberg, CEO of Cantargia.

How CAN04 attacks a cancer tumour

Watch the animated video

Press releases

* (R) = Regulatory press releases

Show more press releases  >>